Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Conditions:   Uterine Cervical Neoplasms;   Cervical Cancer;   Cervical Neoplasms;   Cervix Cancer Interventions:   Drug: Sintilimab;   Drug: quadrivalent HPV vaccine Sponsors:   Buhai Wang;   Innovent Biologics (Suzhou) Co. Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Abstract With more than 3300 new cases and almost 2500 deaths each year, cervical cancer (CC) ranks second among female cancers in Moroccan women. The majority of cases occurs in women aged 50 and over. In absence of a national cancer registry, data published in Morocco are limited to the number of cases recorded in some oncology centers, so the incidence of this cancer is likely much higher than estimated. A Moroccan national program against CC based on the practice of visual inspection after application of acetic acid was set up in 2010, allowing both screening and possibly immediate treatment of (pre)cancerous ...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
This study aimed to describe and compare vaccine intention among young females with and without a cancer history, in addition to identifying factors associated with a HPV vaccination intention. Vaccine-na ïve females (aged 18–26 years,n = 120) and maternal caregivers with vaccine-naïve daughters (aged 9–17 years,n = 197) completed surveys querying HPV vaccination intention, HPV knowledge, and communication, along with sociodemographic, medical, and health belief factors. Multivariable logistic regression was utilized to calculate odds ratio (OR) and 95% confidence...
Source: Journal of Clinical Psychology in Medical Settings - Category: Psychiatry & Psychology Source Type: research
Cervical cancer (CC) control is based on the implementation of effective screening programs. In the coming years, human papilloma virus vaccination coverage will contribute considerably toward cancer prevention. In Italy, where an organized screening program has been implemented, immigration from low/middle-income countries with a high prevalence of human papilloma virus infections has increased steadily over the last decades. To assess the impact of screening efforts in counteracting background changes, we analyzed the incidence trends of cervical intraepithelial neoplasia grade 3 carcinomas in situ (CIS) and invasive CC ...
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Research Papers: Gynecological Cancer Source Type: research
Authors: Park YC, Ouh YT, Sung MH, Park HG, Kim TJ, Cho CH, Park JS, Lee JK Abstract OBJECTIVE: Persistent infection of HPV increases the chance of carcinoma in situ of cervix through stages of cervical intraepithelial neoplasia (CIN) 1, 2, and 3, and finally progresses into cervical cancer. We aimed to explore the safety and efficacy of BLS-M07 which is orally administered agent expressing human papillomavirus (HPV) 16 E7 antigen on the surface of Lactobacillus casei in patients with CIN 3. METHODS: Patients with CIN 3 were recruited in our clinical trial. Reid Colposcopic Index (RCI) grading and serum HPV16 E...
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
OBJECTIVE: To evaluate the knowledge and acceptability of the human papillomavirus (HPV) vaccine among health professionals from western Amazonia. METHODS: A cross-sectional study was conducted in the Sistema Assistencial è Saúde da Mulher e da Criança (Health Care System for Women and Children; SASMC) in Acre, Brazil, in 2017. The participants comprised 196 health professionals. The data collection instrument contained 31 questions about HPV, its clinical repercussions for women, and the HPV vaccine. Quantitative variables were presented as medians and 95% confidence intervals (CIs), and p
Source: Clinics - Category: General Medicine Source Type: research
Conclusions The prevalence of the LR-HPV in high-grade squamous intraepithelial lesion cervical lesions is low but is expected to increase in the future because of the expected decrease in CC caused by HPV types that are included in the bi-, quadri-, and nanovalent vaccine. The CIN 2–3 and CC patients with LR-HPV types and with negative HPV, challenge HPV screening sensitivity, which is based on a limited number of HR-HPV types.
Source: Journal of Lower Genital Tract Disease - Category: OBGYN Tags: Original Research Articles: Cervix and HPV Source Type: research
This study provides an array of HPV vaccination messages and dissemination strategies for optimizing HPV vaccination rates.
Source: Journal of Cancer Education - Category: Cancer & Oncology Source Type: research
Conclusion: Sub-Saharan countries still have a long way to go in controlling the high burden of cervical cancer. Effective prevention methods exist, such as HPV vaccination and screening, but their affordability and implementation remain challenging for most of these countries. Despite that, there is still light on the horizon, as the cost of HPV vaccines has been steadily decreasing and most African countries are using the more cost-effective methods of cervical cancer screening. PMID: 31552125 [PubMed]
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
CONCLUSIONS: A small proportion of Latvian women are over-screened, whereas many women remain unscreened. The main contributing factor for this was their poor understanding of the roles that cervical screening and HPV vaccination play in preventing CC. PMID: 31545387 [PubMed - in process]
Source: Acta Dermatovenerologica Alpina, Panonica, et Adriatica - Category: Dermatology Tags: Acta Dermatovenerol Alp Pannonica Adriat Source Type: research
Conditions:   Uterine Cervical Neoplasms;   Cervical Cancer;   Cervical Neoplasms;   Cervix Cancer Interventions:   Drug: Sintilimab;   Drug: quadrivalent HPV vaccine Sponsors:   Buhai Wang;   Innovent Biologics (Suzhou) Co. Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Research | Vaccines